These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

574 related items for PubMed ID: 18833073

  • 1. Biological agents in the treatment of psoriasis.
    Tzu J, Krulig E, Cardenas V, Kerdel FA.
    G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
    [Abstract] [Full Text] [Related]

  • 2. Biologic therapeutics in the treatment of psoriasis. Part 1: review.
    Langley RG, Gupta AK, Cherman AM, Inniss KA.
    J Cutan Med Surg; 2007 Oct; 11(3):99-122. PubMed ID: 17511926
    [Abstract] [Full Text] [Related]

  • 3. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM, Bottino CJ, Lindholm J, Buchholz R.
    J Drugs Dermatol; 2005 Oct; 4(5):544-55. PubMed ID: 16167412
    [Abstract] [Full Text] [Related]

  • 4. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
    Bos WE, Thio HB, Neumann HA, van der Fits L, Prens EP.
    Ned Tijdschr Geneeskd; 2006 May 13; 150(19):1065-70. PubMed ID: 16733982
    [Abstract] [Full Text] [Related]

  • 5. A review of biologic treatments for psoriasis with emphasis on infliximab.
    Pirzada S, Tomi Z, Gulliver W.
    Skin Therapy Lett; 2007 Apr 13; 12(3):1-4. PubMed ID: 17487347
    [Abstract] [Full Text] [Related]

  • 6. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R, Reich K.
    Curr Probl Dermatol; 2009 Apr 13; 38():107-136. PubMed ID: 19710553
    [Abstract] [Full Text] [Related]

  • 7. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
    Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR.
    J Dermatolog Treat; 2011 Apr 13; 22(2):65-74. PubMed ID: 20443663
    [Abstract] [Full Text] [Related]

  • 8. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM, Saini R, Tutrone WD.
    J Drugs Dermatol; 2002 Dec 13; 1(3):303-10. PubMed ID: 12851990
    [Abstract] [Full Text] [Related]

  • 9. Biologic agents in the treatment of psoriasis.
    Guarneri F, Guarneri C, Guarneri B.
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov 13; 1(3):193-217. PubMed ID: 19075983
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
    Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A.
    Br J Dermatol; 2008 Aug 13; 159(2):274-85. PubMed ID: 18547300
    [Abstract] [Full Text] [Related]

  • 11. Biologicals in the treatment of psoriasis.
    Boker A, Kimball AB, Rolz-Cruz G.
    Curr Opin Investig Drugs; 2007 Nov 13; 8(11):939-46. PubMed ID: 17979028
    [Abstract] [Full Text] [Related]

  • 12. The effect of weight on the efficacy of biologic therapy in patients with psoriasis.
    Clark L, Lebwohl M.
    J Am Acad Dermatol; 2008 Mar 13; 58(3):443-6. PubMed ID: 18083274
    [Abstract] [Full Text] [Related]

  • 13. Update on the mechanisms and efficacy of biological therapies for psoriasis.
    Koo J, Khera P.
    J Dermatol Sci; 2005 May 13; 38(2):75-87. PubMed ID: 15862940
    [Abstract] [Full Text] [Related]

  • 14. Biologic therapies in psoriasis: a new therapeutic approach.
    Gisondi P, Girolomoni G.
    Autoimmun Rev; 2007 Sep 13; 6(8):515-9. PubMed ID: 17854741
    [Abstract] [Full Text] [Related]

  • 15. Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus.
    Saini R, Tutrone WD, Weinberg JM.
    Curr Pharm Des; 2005 Sep 13; 11(2):273-80. PubMed ID: 15638763
    [Abstract] [Full Text] [Related]

  • 16. [Biologics in the treatment of psoriasis].
    Dissemond J, Grabbe S.
    MMW Fortschr Med; 2006 Sep 21; 148(38):42-4. PubMed ID: 17036963
    [Abstract] [Full Text] [Related]

  • 17. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis.
    Weinberg JM.
    Clin Ther; 2003 Oct 21; 25(10):2487-505. PubMed ID: 14667953
    [Abstract] [Full Text] [Related]

  • 18. Newer treatment options for patients with moderate-to-severe psoriatic disease.
    Roebuck HL.
    Nurse Pract; 2006 Aug 21; 31(8):5-6,11. PubMed ID: 16966969
    [No Abstract] [Full Text] [Related]

  • 19. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
    Weinberg JM, Saini R.
    Cutis; 2003 Jan 21; 71(1):25-9. PubMed ID: 12553627
    [Abstract] [Full Text] [Related]

  • 20. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J, Burden AD.
    Br J Dermatol; 2012 Nov 21; 167 Suppl 3():12-20. PubMed ID: 23082811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.